Edition:
United Kingdom

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

13.51USD
22 Jan 2019
Change (% chg)

$-0.30 (-2.17%)
Prev Close
$13.81
Open
$13.73
Day's High
$13.86
Day's Low
$13.48
Volume
26,121
Avg. Vol
43,259
52-wk High
$18.00
52-wk Low
$7.50

Latest Key Developments (Source: Significant Developments)

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Lonafarnib For Treatment Of Hepatitis Delta Virus Infection
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION GRANTED BY FDA FOR LONAFARNIB FOR TREATMENT OF HEPATITIS DELTA VIRUS (HDV) INFECTION.  Full Article

Eiger Biopharmaceuticals Says >$100 Mln In Cash Available To Achieve Key Milestones
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS INC - ON 2018 RESEARCH AND DEVELOPMENT DAY, MORE THAN $100 MILLION IN CASH AVAILABLE TO ACHIEVE KEY MILESTONES.  Full Article

Eiger Biopharma Announces FDA Acceptance Of IND Application For Progeria Treatment
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR LONAFARNIB FOR THE TREATMENT OF PROGERIA AND PROGEROID LAMINOPATHIES.EIGER BIOPHARMACEUTICALS INC - PLANS TO FILE NDA IN 2019.  Full Article

Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EIGER BIOPHARMACEUTICALS INC - PLANS TO USE PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB FOR HEPATITIS DELTA VIRUS.EIGER BIOPHARMACEUTICALS INC - PLANS TO USE PROCEEDS TO FUND REGULATORY ADVANCEMENT OF LONAFARNIB RELATED TO TREATMENT OF PROGERIA.  Full Article

Eiger Announces FDA Guidance On HDV Phase 3 Study Design; Primary Endpoint Established
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES FDA GUIDANCE ON HDV PHASE 3 STUDY DESIGN: PRIMARY ENDPOINT ESTABLISHED; D-LIVR STUDY INITIATING Q4 2018.EIGER BIOPHARMACEUTICALS - RECEIVED WRITTEN GUIDANCE FROM FDA, CONFIRMING CONCURRENCE ON PIVOTAL TRIAL DESIGN, INCLUDING PRIMARY ENDPOINT FOR D-LIVR.  Full Article

Eiger Biopharmaceuticals Q4 Loss Per Share $1.11
Monday, 12 Mar 2018 

March 12 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.11.Q4 EARNINGS PER SHARE VIEW $-1.02 -- THOMSON REUTERS I/B/E/S.‍CASH RUNWAY EXTENDS THROUGH MID-2019​.  Full Article

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article

EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Eiger Biopharmaceuticals Inc :EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.8 MILLION SHARES AT $10.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS & COMMISSIONS​.  Full Article